Floatz Rating
C36/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
radiopharmaceutical
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06287944CT.gov 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Indium In 111-Dota-Daratumumab (this asset) | City of Hope Medical Center | P1 | C · 36 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Idarubicin | Institute of Hematology & Blood Diseases Hospital, China | P4 | BB |
| Daunomycin | Shen yang | P4 | BB |
| Amsacrine | University Hospital, Toulouse | P4 | BB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P4 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Indium In 111-Dota-Daratumumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P1 | CC · 43 |
| Myelodysplastic Syndrome | — | P1 | C · 39 |
| Acute Lymphoblastic Leukemia | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Indium In 111-Dota-Daratumumab in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/indium-in-111-dota-daratumumab-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →